NASDAQ · JYNT

The Joint Corp.

Healthcare · Medical - Care Facilities

$8.44▲ 0.12% ($0.01)at close

After hours$8.31▼ 1.54%7:30 PM ET

52-week

$7.50$10.67

Market cap

$120.32M

P/E

31.66

EPS (TTM)

$0.27

Next earnings

Nov 5, 2026

What the market price implies · Reverse DCF

To support a price of $8.44, this model requires revenue to grow by 21.62%/yr over the next 10 years, compounded annually.

Historical revenue grew by -8.99%/yr over the past 4 years. The required annual growth rate is 30.61 percentage points higher.

Selected forecast · Base scenario

2.27%/yr · actual 10-year annualized revenue growth

Year 1 growth: 3.55%

Market-implied · Base operating assumptions + edited margins

21.62%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$8.44

Estimated value / share

$3.04

Base scenario

This estimate is 64.03% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 3.55% · Ending margin 2.45% · Discount rate 10.82%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 20, 2026, 8:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionHigh confidence

1Y Price: -17.74%Revenue (TTM): 220.62%FCF (TTM): 25.05%P/FCF: 20th pct

What changed

The stock fell 17.74% over the last year. Revenue grew 220.62% over the trailing twelve months. Operating margin moved from -6.37% to 2.45%. Free cash flow grew 25.05% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price, and the shares now sit around the 20th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.

What would invalidate this read

This read changes if operating margin (currently 2.45%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers.

CEOSanjiv Razdan

SectorHealthcare

IndustryMedical - Care Facilities

Employees330

IPO dateNov 11, 2014

https://www.thejoint.com

Market multiples

Forward P/E—

EV/EBITDA74.37

Enterprise value$110.38M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth14.41%

Gross margin (FY2025)79.55%▲1.6ppvs FY2024

Operating margin (FY2025)-1.65%▲2.0ppvs FY2024

ROE19.43%▲3.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$20.00▲136.97%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est $0.11 · Revenue est $14.85M

View

NASDAQ · JYNT

The Joint Corp.

Healthcare · Medical - Care Facilities

$8.44▲ 0.12% ($0.01)at close

After hours$8.31▼ 1.54%7:30 PM ET

52-week

$7.50$10.67

Market cap

$120.32M

P/E

31.66

EPS (TTM)

$0.27

Next earnings

Nov 5, 2026

What the market price implies · Reverse DCF

To support a price of $8.44, this model requires revenue to grow by 21.62%/yr over the next 10 years, compounded annually.

Historical revenue grew by -8.99%/yr over the past 4 years. The required annual growth rate is 30.61 percentage points higher.

Selected forecast · Base scenario

2.27%/yr · actual 10-year annualized revenue growth

Year 1 growth: 3.55%

Market-implied · Base operating assumptions + edited margins

21.62%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$8.44

Estimated value / share

$3.04

Base scenario

This estimate is 64.03% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 3.55% · Ending margin 2.45% · Discount rate 10.82%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 20, 2026, 8:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionHigh confidence

1Y Price: -17.74%Revenue (TTM): 220.62%FCF (TTM): 25.05%P/FCF: 20th pct

What changed

What the market seems to be pricing

What would invalidate this read

This read changes if operating margin (currently 2.45%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers.

CEOSanjiv Razdan

SectorHealthcare

IndustryMedical - Care Facilities

Employees330

IPO dateNov 11, 2014

https://www.thejoint.com

Market multiples

Forward P/E—

EV/EBITDA74.37

Enterprise value$110.38M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth14.41%

Gross margin (FY2025)79.55%▲1.6ppvs FY2024

Operating margin (FY2025)-1.65%▲2.0ppvs FY2024

ROE19.43%▲3.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$20.00▲136.97%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est $0.11 · Revenue est $14.85M

View